Lincoln Pharmaceuticals (NSE:LINCOLN) Cyclically Adjusted Revenue per Share: ₹290.25 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:LINCOLN Lincoln Pharmaceuticals Ltd NSE:LINCOLN
82 GF Score
Price ₹580.75
GF Value ₹722.01
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share?

Lincoln Pharmaceuticals NSE:LINCOLN +0.62% 82 Cyclically Adjusted Revenue per Share is ₹290.25 as of Mar. 2026. GuruFocus rates NSE:LINCOLN with a GF Score™ of 82/100 and a GF Value™ of ₹722.01 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lincoln Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was ₹93.522. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹290.25 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Lincoln Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Lincoln Pharmaceuticals was 6.80% per year. The lowest was 4.70% per year. And the median was 6.40% per year.

As of today (2026-08-04), Lincoln Pharmaceuticals's current stock price is ₹580.75. Lincoln Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹290.25. Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 2.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lincoln Pharmaceuticals was 3.29. The lowest was 0.96. And the median was 1.70.


Lincoln Pharmaceuticals  (NSE:LINCOLN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=580.75/290.25
=2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lincoln Pharmaceuticals was 3.29. The lowest was 0.96. And the median was 1.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Lincoln Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Lincoln Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 234.23 253.09 270.56 282.67 290.25

Lincoln Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 282.67 287.19 290.47 290.76 290.25

NSE:LINCOLN vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lincoln Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


NSE:LINCOLN
82GF Score
Lincoln Pharmaceuticals Ltd NSE:LINCOLN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lincoln Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=93.522/164.2724*164.2724
=93.522

Current CPI (Mar. 2026) = 164.2724.

Lincoln Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 54.728 105.961 84.845
201609 45.557 105.961 70.627
201612 35.137 105.196 54.869
201703 59.504 105.196 92.920
201706 74.924 107.109 114.911
201709 44.814 109.021 67.525
201712 40.102 109.404 60.214
201803 30.831 109.786 46.132
201806 49.886 111.317 73.618
201809 51.302 115.142 73.192
201812 42.186 115.142 60.187
201903 34.990 118.202 48.628
201906 48.370 120.880 65.734
201909 56.361 123.175 75.166
201912 49.304 126.235 64.160
202003 34.396 124.705 45.309
202006 51.905 127.000 67.138
202009 63.057 130.118 79.609
202012 57.282 130.889 71.892
202103 35.014 131.771 43.650
202106 61.015 134.084 74.752
202109 63.661 135.847 76.982
202112 59.865 138.161 71.179
202203 49.269 138.822 58.302
202206 61.606 142.347 71.095
202209 70.208 144.661 79.726
202212 66.783 145.763 75.263
202303 53.494 146.865 59.835
202306 67.691 150.280 73.994
202309 77.897 151.492 84.469
202312 73.119 152.924 78.545
202403 66.474 153.035 71.355
202406 73.542 155.789 77.547
202409 80.514 157.882 83.773
202412 73.173 158.323 75.923
202503 83.982 157.552 87.564
202506 76.937 159.755 79.112
202509 81.584 162.289 82.581
202512 83.045 163.281 83.549
202603 93.522 164.272 93.522

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹290.25 mean?
Lincoln Pharmaceuticals (NSE:LINCOLN) has a Cyclically Adjusted Revenue per Share of ₹290.25 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lincoln Pharmaceuticals and its competitors.
Is Lincoln Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Lincoln Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹290.25. Overall, Lincoln Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lincoln Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Lincoln Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹290.25 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lincoln Pharmaceuticals and its competitors. Lincoln Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹290.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lincoln Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals (NSE:LINCOLN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹722.01, compared to a current price of ₹580.75 — trading 19.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹290.25. Lincoln Pharmaceuticals' overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Lincoln Pharmaceuticals (NSE:LINCOLN), the current Cyclically Adjusted Revenue per Share is ₹290.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued. The current stock price of ₹580.75 is trading 19.6% below its estimated GF Value™ of ₹722.01. GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:LINCOLN:

  • Cyclically Adjusted Revenue per Share: ₹290.25
  • GF Value™: ₹722.01 vs. price of ₹580.75 (19.6% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lincoln Pharmaceuticals Business Description

Other Exchanges 531633:India
Address Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
82GF Score

Get the complete analysis for NSE:LINCOLN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹580.75
Price
₹722.01
GF Value